When: $242 reclaim with volume >12M

Then: Deploy 25% of position

REDUCE POSITION SIZE; ENTER LOWER; MOVE STOP BELOW 200 SMA; REQUIRE Q3 CONFIRMATION

• Q2 FY27 revenue growth of 10.8% includes Informatica acquisition, making organic growth closer to 9-10%
• Q2 FY27 net income up 87% YoY includes $2.6 billion one-time gain on sale of securities; normalized EPS closer to $1.65 not $4.29
• Forward EPS assumption of $16-plus underpinning $290-$320 fair value is inflated by non-recurring items
• 10-year Treasury at highest level since 2002; 97% Polymarket odds of no 2026 rate cuts does not mean rates have peaked
• Short-term technicals show descending channel with lower highs: 263.97, 258.97, 250.10, 238.22, 236.69 since September 3rd
• MACD bearish cross active since September 8th; price below Bollinger middle band for three consecutive sessions
• Current bounce on 9.56 million shares versus 55-million-share spike on prior rally; buyers from initial move likely sitting on profits
• Stop at $215 is 9.7% below $238 entry; 200 SMA at $199.74 is 16% below — bounded downside assumes 200 SMA holds
• Upside targets of $290-$320 require multiple expansion to 18-20x forward earnings; CRM hasn't consistently traded at that level in 2002-yield environment
• Current ratio deteriorated from 1.06 to 0.76; net debt swung to $7.1 billion from net cash post-Informatica
• SBC of $3.5 billion annually represents ~24% of stated FCF being used for equity compensation
• Goodwill of $57.9 billion creates impairment tail risk on Slack, Tableau, and Informatica
• Recommended position sizing of 2-3% for beta 1.20 name with $9 ATR, not 7-8%

→ vs aggressive: The 10.8% revenue growth cited as proof of re-acceleration includes the inorganic Informatica acquisition; organic growth remains 9-10%

→ vs aggressive: Q2 net income up 87% includes $2.6 billion one-time gain; normalized EPS is $1.65 not $4.29, making the $290-$320 price target built on inflated assumptions

→ vs aggressive: The 10-year Treasury at 2002 highs with 97% odds of no 2026 cuts is a moving target, not a stable priced-in constraint; rising yields compress multiples regardless of earnings

→ vs aggressive: Short-term technicals show lower highs and lower lows since September 3rd, not a 'healthy correction' — the descending channel contradicts consolidation narrative

→ vs aggressive: Low-volume bounce after a 55-million-share spike and 28% rally in six sessions suggests buyers from the initial move are sitting on profits

→ vs aggressive: The 2.5:1 risk-reward assumes 200 SMA holds and multiple expansion to 18-20x occurs — stacked conditional assumptions, not asymmetry

→ vs aggressive: Q3 catalyst is binary; in-line results mean no multiple expansion in a 21x earnings stock with rising rates, while Agentforce miss risks 10-15% gap down

→ vs aggressive: Balance sheet deterioration (current ratio 1.06 to 0.76, net debt $7.1B, goodwill $57.9B) undermines 'FCF compounder' narrative

BUY with 3-4% position size, scaled entry starting 33-40% at 236-240, 25% at 225-230, 25% on reclaim of 242.42; stop at 215; take 30-40% off if Q3 print delivers gap to 265-275

• Operating margin transformation from 5.9% to 21.5% over three years is real but already priced in at 14.8x forward earnings
• Organic revenue growth stabilizes at 9-10% even after backing out 100-150 bps Informatica contribution from 10.8% reported Q2 growth
• Forward EPS estimate of 16-plus is built on full-year operating model despite Q2 net income inflated by $2.6 billion one-time gain on securities; normalized Q2 EPS closer to 1.65 versus 4.29
• Realistic 12-month target is 270-280 rather than 290-320, with risk-reward closer to 1.8 to 1 instead of 2.5 to 1
• Stock is in technical consolidation phase after parabolic move from 205 to 264 in six sessions on 55-million-share spike; 50 SMA at 218, lower Bollinger band at 220.59
• Macro presents a real ceiling on multiple expansion requiring either rate relief or CRM upside surprise to reach full target
• Structural quality case intact but tactical setup doesn't yet reward maximum aggression; 215 stop preferred over 199
• Pre-commit to taking 30-40% off position on Q3 gap to 265-275 rather than holding for full 290-320 target in current rate environment

→ vs aggressive: Macro is not a solved problem; 14.8x forward P/E reflects market pricing continued execution, and compression has only partially played out with next directional move uncertain

→ vs aggressive: Position size of 7-8% is too aggressive for single high-conviction name with beta-1.20 and binary catalyst in a macro-constrained, technically consolidating setup; 3-5% range is appropriate, this sits at lower end

→ vs aggressive: Full 290-320 target assumes macro cooperates but ignores need for exit discipline; ceiling is real and extension may not come in current rate environment

→ vs conservative: 9-10% organic growth is stabilization not deceleration; underlying business is not broken but rather mature high-quality compounder at 21.5% operating margins

→ vs conservative: EPS inflation from $2.6 billion gain is a risk factor for price target but not a thesis-killer; Street already normalized forward estimates

→ vs conservative: Stop at 199 is too loose at 16% drawdown; 215 stop preserves risk discipline while not invalidating thesis until 50 SMA breaks with conviction

→ vs conservative: Descending channel entry concern is valid but doesn't negate BUY decision; justify scaling to 33-40% rather than 50% at current level